A Phase 3 Trial of Semagacestat for Treatment of Alzheimer's Disease
The DOI matches its Crossref record; 23 of the 24 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Alzheimer's disease is characterized by the presence of cortical amyloid-beta (Aβ) protein plaques, which result from the sequential action of β-secretase and γ-secretase on amyloid precursor protein. Semagacestat is a small-molecule γ-secretase inhibitor that was developed as a potential treatment for Alzheimer's disease. METHODS: We conducted a double-blind, placebo-controlled trial in which 1537 patients with probable Alzheimer's disease underwent randomization to receive 100 mg of semagacestat, 140 mg of semagacestat, or placebo daily. Changes in cognition from baseline to week 76 were assessed with the use of the cognitive subscale of the Alzheimer's Disease Assessment Scale for cognition (ADAS-cog), on which scores range from 0 to 70 and higher scores indicate greater cognitive impairment, and changes in functioning were assessed with the Alzheimer's Disease Cooperative Study-Activities of Daily Living (ADCS-ADL) scale, on which scores range from 0 to 78 and higher scores indicate better functioning. A mixed-model repeated-measures analysis was used. RESULTS: The trial was terminated before completion on the basis of a recommendation by the data and safety monitoring board. At termination, there were 189 patients in the group receiving placebo, 153 patients in the group receiving 100 mg of semagacestat, and 121 patients in the group receiving 140 mg of semagacestat. The ADAS-cog scores worsened in all three groups (mean change, 6.4 points in the placebo group, 7.5 points in the group receiving 100 mg of the study drug, and 7.8 points in the group receiving 140 mg; P=0.15 and P=0.07, respectively, for the comparison with placebo). The ADCS-ADL scores also worsened in all groups (mean change at week 76, -9.0 points in the placebo group, -10.5 points in the 100-mg group, and -12.6 points in the 140-mg group; P=0.14 and P<0.001, respectively, for the comparison with placebo). Patients treated with semagacestat lost more weight and had more skin cancers and infections, treatment discontinuations due to adverse events, and serious adverse events (P<0.001 for all comparisons with placebo). Laboratory abnormalities included reduced levels of lymphocytes, T cells, immunoglobulins, albumin, total protein, and uric acid and elevated levels of eosinophils, monocytes, and cholesterol; the urine pH was also elevated. CONCLUSIONS: As compared with placebo, semagacestat did not improve cognitive status, and patients receiving the higher dose had significant worsening of functional ability. Semagacestat was associated with more adverse events, including skin cancers and infections. (Funded by Eli Lilly; ClinicalTrials.gov number, NCT00594568.)
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Additionally, participants experienced adverse reactions such as gastrointestinal symptoms, skin cancer, and infections, which are speculated to be related to the inhibition of other γ-secretase substrates, including notch, CD44, ErbB4, and cadherin.438–441”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [438]
In the citing paper
“Disappointingly, the use of γ-secretase inhibitors (GSIs) has shown limited efficacy in treating Alzheimer's disease [113].”
From The low-density lipoprotein receptor: Emerging post-transcriptional regulatory mechanisms (2025) · cites this paper as [113]
In the citing paper
“Several drugs that have shown promising results in Alzheimer mouse models have failed to prevent cognitive decline in late-phase clinical trials87–89.”
From The use of brain organoids to investigate neural development and disease (2017) · cites this paper as [88]
In the citing paper
“However, with the failures or unsatisfactory efficacy of drugs anti-Aβ [9, 208–211], the development of drugs targeting other targets is increasing, such as anti-tau pathology and anti-neuroinflammation [212].”
From Tau and neuroinflammation in Alzheimer’s disease: interplay mechanisms and clinical translation (2023) · cites this paper as [208]
In the citing paper
“Semagacestat was the first GSI to enter a phase 3 trial for AD. However, the trial was halted early due to concerns of worsening cognition, increased incidence of skin cancers and infection, and weight loss relative to placebo (Doody et al., 2013).”
From Alzheimer Disease: An Update on Pathobiology and Treatment Strategies (2019) · cites this paper as Doody et al., 2013
5 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia
Cummings, J. L., Mega, M., Gray, K., Rosenberg-Thompson, S., Carusi, D. A., & Gornbein, J. (1994) · Neurology · doi:10.1212/wnl.44.12.2308 · Cited by 7,568
An Inventory to Assess Activities of Daily Living for Clinical Trials in Alzheimerʼs Disease
Galasko, D., Bennett, D., Sano, M., Ernesto, C., Thomas, R., Grundman, M., & Ferris, S. (1997) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-199700112-00005 · Cited by 1,194
Self-citationO’Bryant, S. E. (2008) · Archives of Neurology · doi:10.1001/archneur.65.8.1091 · Cited by 884
Wong, G. T., Manfra, D., Poulet, F. M., Zhang, Q., Josien, H., Bara, T., Engstrom, L., Pinzon-Ortiz, M., Fine, J. S., Lee, H.-J. J., et al. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m311652200 · Cited by 718
Mohs, R. C., Knopman, D., Petersen, R. C., Ferris, S. H., Ernesto, C., Grundman, M., Sano, M., Bieliauskas, L., Geldmacher, D., Clark, C., et al. (1997) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-199700112-00003 · Cited by 692
Self-citationClinical Gerontology: A Guide to Assessment and Intervention
Brink, T. L. (1986) · Medical Entomology and Zoology · Cited by 594
Geling, A., Steiner, H., Willem, M., Bally‐Cuif, L., & Haass, C. (2002) · The EMBO Reports · doi:10.1093/embo-reports/kvf124 · Cited by 497
The mechanism of γ‐Secretase dysfunction in familial Alzheimer disease
Chávez‐Gutiérrez, L., Bammens, L., Benilova, I., Vandersteen, A., Benurwar, M., Borgers, M., Lismont, S., Zhou, L., Van Cleynenbreugel, S., Esselmann, H., et al. (2012) · The EMBO Journal · doi:10.1038/emboj.2012.79 · Cited by 495
Research works printed but not linked: 2
- Wimo A, Wetterholm A-L, Mastey V, Winbald B. Evaluation of the healthcare resource utilization and caregiver time in anti-dementia drug trials. In: Wimo A, Jönsson B, Karlsson G, Winblad B, eds. The health economics of dementia. London: Wiley, 1998:465-99.
- Kind P. The EuroQol instrument: an index of health-related quality of life. In: Spilker B, ed. Quality of life and pharmacoeconomics in clinical trials. 2nd ed. Philadelphia: Lippincott-Raven, 1996:191-201.
Cited by
Items 601–700 of 1,002
A Bayesian Exposure-Time Method for Clinical Trial Safety Monitoring With Blinded Data
Schnell, P., & Ball, G. (2016) · Therapeutic Innovation & Regulatory Science · doi:10.1177/2168479016656702 · Cited by 23
Aquino, C. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.694329 · Cited by 24
“Semagecestatv (40) γ-secretase inhibitor Mild to moderate 100, 140mg, or”
BackgroundDoering, S., McCullough, A. A., Gordon, B. A., Chen, C. D., McKay, N. S., Hobbs, D. A., Keefe, S., Flores, S. E., Scott, J., Smith, H. D., et al. (2024) · EBioMedicine · doi:10.1016/j.ebiom.2024.105080 · Cited by 24
Self-citationYonemura, Y., Futai, E., Yagishita, S., Kaether, C., & Ishiura, S. (2016) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.09.018 · Cited by 23
Protein aggregation and neurodegenerative disease: Structural outlook for the novel therapeutics
Arar, S. H., Haque, M. A., & Kayed, R. (2023) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.26561 · Cited by 23
“…depletion of endogenous proteins, deterioration of motor functional capability, higher occurrence of malignant melanoma and cutaneous melanoma, increased infections in clinical trials patients acquiring drug as compared to placebo 238,239 and successive loss of associated cellular functions.”
Desmoid-type fibromatosis: Current therapeutic strategies and future perspectives
Ibrahim, R., Assi, T., Khoury, R., Duong-Ngo, C., Faron, M., Verret, B., Lévy, A., Honoré, C., Henon, C., Pechoux, C. L., et al. (2023) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2023.102675 · Cited by 22
Amyloid‐β in Alzheimer's disease: Structure, toxicity, distribution, treatment, and prospects
Yu, Y., Yu, S., Battaglia, G., & Tian, X. (2024) · Ibrain · doi:10.1002/ibra.12155 · Cited by 38
Bhatt, A., Bhardwaj, H., & Srivastava, P. (2024) · Neuroscience · doi:10.1016/j.neuroscience.2024.07.019 · Cited by 23
Roher, A. E., Maarouf, C. L., & Kokjohn, T. A. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-150757 · Cited by 24
“Instead, the semagacestat treatment regimen probably perturbed Notch1 signaling thereby inducing the development of skin cancers and most likely altered other -secretase enzyme-substrate kinetics generating toxic conditions that accelerated the clinical course of AD dementia [28].”
BackgroundSmall Molecules That Inhibit Notch Signaling
de Kloe, G. E., & Strooper, B. D. (2014) · Methods in molecular biology · doi:10.1007/978-1-4939-1139-4_23 · Cited by 23
Mondal, S., Vashi, Y., Ghosh, P., Roy, D., Barthakur, M., Kumar, S., & Iyer, P. K. (2020) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.0c00387 · Cited by 22
Ugbaja, S. C., Sanusi, Z. K., Appiah‐Kubi, P., Lawal, M. M., & Kumalo, H. M. (2020) · Biophysical Chemistry · doi:10.1016/j.bpc.2020.106536 · Cited by 24
CORRELATION BETWEEN COGNITION AND FUNCTION ACROSS THE SPECTRUM OF ALZHEIMER’S DISEASE
Liu-Seifert, H., Siemers, E., Selzler, K. J., Sundell, K., Aisen, P. S. S., Cummings, J. L., Raskin, J., & Mohs, R. C. (2016) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2016.99 · Cited by 24
Self-citationAlzheimer’s Disease: Dawn of a New Era?
Amirrad, F., Bousoik, E., Shamloo, K., Al-Shiyab, H., Nguyen, V.-H. V., & Montazeri Aliabadi, H. (2017) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.18433/j3vs8p · Cited by 21
“Moreover, cognition and function not only did not improve but worsened in all treatment groups (85).”
BackgroundPresenilin, γ-Secretase, and the Search for Pathogenic Triggers of Alzheimer’s Disease
Wolfe, M. S. (2025) · Biochemistry · doi:10.1021/acs.biochem.4c00830 · Cited by 21
Zhang, H., Wang, H., Jing, Z., Liu, B., Wang, X., Li, Y., Luo, H.-M., Lv, H., Tao, X., Timashev, P. S., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1567524 · Cited by 28
“…function is closely related to Notch signaling (100). g -Secretase inhibitors (GSIs) were fi rst used in clinical trials for the treatment of Alzheimer ’ s disease (AD), but the trial was discontinued before completion of the phase III trial due to severe Notch-related adverse events (101).”
Recent Advances in Antibody Therapy for Alzheimer’s Disease: Focus on Bispecific Antibodies
Yang, H. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26136271 · Cited by 21
A review of therapeutic failures in late-stage clinical trials
Jain, R., Subramanian, J., & Rathore, A. S. (2022) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2022.2161366 · Cited by 25
“It was terminated early as it worsened the cognitive and functional status along with increased risk of skin cancer as compared to patients who received placebo [62].”
BackgroundMishra, K. A., & Sethi, K. K. (2024) · Archiv der Pharmazie · doi:10.1002/ardp.202400748 · Cited by 23
Amyloid-beta metabolism in age-related neurocardiovascular diseases
Aivalioti, E., Georgiopoulos, G. A., Tual‐Chalot, S., Bampatsias, D., Delialis, D., Sopova, K., Drakos, S. G., Stellos, K., & Stamatelopoulos, K. S. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae655 · Cited by 24
“221 Amyloid-beta–degrading enzymes as possible therapeutic targets ( Figure 2 )”
Hölttä, M., Dean, R. A., Siemers, E., Mawuenyega, K. G., Sigurdson, W. C., May, P. C., Holtzman, D. M., Portelius, E., Zetterberg, H., Bateman, R. J., et al. (2016) · Alzheimer s Research & Therapy · doi:10.1186/s13195-016-0178-x · Cited by 21
Self-citationBeyond immunotherapy: new approaches for disease modifying treatments for early Alzheimer’s disease
Ruthirakuhan, M. T., Herrmann, N., Suridjan, I., Abraham, E. H., Farber, I., & Lanctôt, K. L. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2016.1258060 · Cited by 27
“The inhibition of Notch cleavage is thought to mediate some toxic adverse effects associated with this drug class, such as weight loss, skin cancer, and infections [40,41].”
BackgroundBernstein, O. M., Grill, J. D., & Gillen, D. L. (2021) · Alzheimer s Research & Therapy · doi:10.1186/s13195-020-00762-8 · Cited by 21
Zhao, H., Huang, X., & Tong, Z. (2021) · ChemMedChem · doi:10.1002/cmdc.202100428 · Cited by 23
AMBAR, an Encouraging Alzheimer's Trial That Raises Questions
Loeffler, D. A. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2020.00459 · Cited by 22
“The amyloid hypothesis (1) led to efforts to treat Alzheimer’s disease (AD) by reducing brain Aβ, including vaccination (2), anti-Aβ antibodies (3–7), Aβ aggregation inhibitors (8), β-secretase inhibitors (9), and γ-secretase modulators (10), and inhibitors (11).”
BackgroundStructural and Chemical Biology of Presenilin Complexes
Johnson, D. S., Li, Y., Pettersson, M., & George‐Hyslop, P. S. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a024067 · Cited by 21
“Despite encouraging results obtained from earlier clinical investigations (Siemers et al. 2007), the phase III trial failed because of the unexpected observation that semagacestat caused worsening of memory in patients (Doody et al. 2013).”
ResultFailure After Failure. What Next in AD Drug Development?
Aisen, P. S. S. (2019) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2019.23 · Cited by 23
Self-citationLUXTON, D. E. A., Thorpe, N., Crane, E., Warne, M., Cornwall, O., El-Dalil, D., Matthews, J., & Rajkumar, A. P. (2025) · The British Journal of Psychiatry · doi:10.1192/bjp.2025.11 · Cited by 22
Therapeutic Advances in Targeting the Amyloid-β Pathway for Alzheimer’s Disease
Zhang, B., Li, Y., Li, H., Shen, X., & Zhu, Z. (2025) · Brain Sciences · doi:10.3390/brainsci15101101 · Cited by 22
“However, two Phase 3 trials conducted in mild-to-moderate AD (2008–2010) were halted after showing no clinical benefit and, instead, accelerated cognitive decline, along with significant adverse events, such as skin cancers and gastrointestinal symptoms [78].”
Cell-type-resolved genetic variation shapes inflammatory bowel disease risk
Alegbe, T., Harris, B. T., Fachal, L., Ramirez-Navarro, L., Tutert, M., Krzak, M., Ghouraba, M., Strickland, M., Ozols, M., Cohen, C. E., et al. (2026) · Nature · doi:10.1038/s41586-026-10627-z · Cited by 22
“Although γ-secretase inhibitors were developed to reduce this pathogenic cleavage, their clinical use was curtailed by dose-limiting side effects such as weight loss and gastrointestinal bleeding 73,74 .”
Nanomedicine against Alzheimer’s and Parkinson’s Disease
Tandon, A., Singh, S. J., & Chaturvedi, R. K. (2020) · Current Pharmaceutical Design · doi:10.2174/1381612826666201021140904 · Cited by 21
Wang, G., Liu, L., Li, Y., Aschenbrenner, A. J., Bateman, R. J., Delmar, P., Schneider, L. S. S., Kennedy, R., Cutter, G., & Xiong, C. (2022) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12286 · Cited by 23
Hearing loss: The final frontier of pharmacology
Foster, A. C., Jacques, B. E., & Piu, F. (2022) · Pharmacology Research & Perspectives · doi:10.1002/prp2.970 · Cited by 22
Selective inhibitors of the PSEN1–gamma-secretase complex
Serneels, L., Narlawar, R., Pérez‐Benito, L., Municoy, M., Guallar, V., T’Syen, D., Dewilde, M., Bischoff, F., Fraiponts, E., Tresadern, G., et al. (2023) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2023.104794 · Cited by 20
Symptoms and conventional treatments of Alzheimer's disease
Chorawala, M. R., Shah, A. C., Pandya, A. J., Kothari, N. R., & Prajapati, B. G. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13205-6.00009-1 · Cited by 21
Towards a Unitary Hypothesis of Alzheimer’s Disease Pathogenesis
Área-Gómez, E., & Schon, E. A. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-231318 · Cited by 20
Development of disease‐modifying therapies against Alzheimer's disease
Iwatsubo, T. (2024) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.13681 · Cited by 20
Self-citationDrug elucidation: invertebrate genetics sheds new light on the molecular targets of CNS drugs
Dwyer, D. S., Aamodt, E. J., Cohen, B. M., & Buttner, E. A. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00177 · Cited by 21
“This information can then guide the next round of drug discovery and so on. at Parkinson’s disease (Clinicaltrials. gov, 2013), and semagacestat, a γ-secretase inhibitor for the treatment of Alzheimer’s disease (Doody et al., 2013).”
BackgroundKim, D., Kim, Y. S., Shin, D. W., Park, C., & Kang, J.-H. (2016) · Journal of Clinical Neurology · doi:10.3988/jcn.2016.12.4.381 · Cited by 22
Acquired disorders with depigmentation: A systematic approach to vitiliginoid conditions
Saleem, M. D., Oussedik, E., Schoch, J. J., Berger, A. C., & Picardo, M. (2018) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2018.03.063 · Cited by 21
Láinez‐González, D., Serrano‐López, J., & Alonso‐Domínguez, J. M. (2022) · Cancers · doi:10.3390/cancers14061459 · Cited by 20
“These patients were treated with a GSI to block β-amyloid production (GSI450139), and the incidence of non-melanoma skin cancers was 2% in the placebo cohort versus 10–11% in the GSI group [65].”
MethodPerspectives on the Tertiary Prevention Strategy for Alzheimer's Disease
Bu, X., Jiao, S., Lian, Y., & Wang, Y. (2015) · Current Alzheimer Research · doi:10.2174/1567205013666151215110114 · Cited by 22
“Furthermore, AD patients administered semagacestat showed a further decline in cognition and a higher risk of skin cancers and infections [8].”
BackgroundBlain, J., Bursavich, M. G., Freeman, E. A., Hrdlicka, L., Hodgdon, H., Chen, T., Costa, D., Harrison, B. A., Kapadnis, S., Murphy, D. A., et al. (2016) · Alzheimer s Research & Therapy · doi:10.1186/s13195-016-0199-5 · Cited by 21
“This issue has been exemplified in a Phase 3 clinical trial with semagacestat [25] as well as a Phase 2 trial with avagacestat [26].”
Lee, D., Lee, G., & Yoon, D. S. (2018) · The Analyst · doi:10.1039/c7an02013a · Cited by 20
Tau tubulin kinases in proteinopathy
Taylor, L. M., McMillan, P. J., Kraemer, B. C., & Liachko, N. F. (2019) · FEBS Journal · doi:10.1111/febs.14866 · Cited by 20
Visualization of PS/γ-Secretase Activity in Living Cells
Maesako, M., Sekula, N. M., Aristarkhova, A., Feschenko, P., Anderson, L. C., & Berezovska, O. (2020) · iScience · doi:10.1016/j.isci.2020.101139 · Cited by 20
Novel Anti-Neuroinflammatory Properties of a Thiosemicarbazone–Pyridylhydrazone Copper(II) Complex
Choo, X. Y., McInnes, L. E., Grubman, A., Wasielewska, J. M., Belaya, I., Burrows, E. L., Quek, H., Cañas-Martín, J., Loppi, S. H., Sorvari, A., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231810722 · Cited by 20
Stem cells in the treatment of Alzheimer's disease – Promises and pitfalls
Bhatti, J. S., Khullar, N., Mishra, J., Kaur, S., Sehrawat, A., Sharma, E., Bhatti, G. K., Selman, A., & Reddy, P. H. (2023) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2023.166712 · Cited by 22
Abosharaf, H. A., Elsonbaty, Y., Tousson, E., & Mohamed, T. M. (2023) · Journal of Neuroendocrinology · doi:10.1111/jne.13356 · Cited by 19
“10,11 These dismal outcomes emphasize the necessity for a detailed awareness of AD and associated illnesses, including the mechanisms causing the aggregation of A β , tau protein, and other contributing causes.”
BackgroundDistinctive contribution of two additional residues in protein aggregation of Aβ42 and Aβ40 isoforms
Im, D., & Choi, T. S. (2024) · BMB Reports · doi:10.5483/bmbrep.2024-0044 · Cited by 22
“However, the modulation strategy of γ -secretase inevitably leads to side effects (e.g., cognitive deterioration), because the γ -secretase hydrolyzes other transmembrane proteins besides APP (96, 97).”
BackgroundDayarathna, T. K., Roseborough, A. D., Gomes, J., Khazaee, R., Silveira, C. R. A., Borron, K., Yu, S., Coleman, K. K. L., Jesso, S., Finger, E. C., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14087 · Cited by 19
Ashwini, P., Bodhankar, S. L., Muthal, A., Kumar, D., Pawar, A., & Kulkarni, R. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2024.11.016 · Cited by 19
Murakami, K., Watanabe, T., Koike, T., Kamata, M., Igari, T., & Kondo, S. (2015) · Brain Research · doi:10.1016/j.brainres.2015.12.016 · Cited by 21
Lessard, C. B., Rodriguez, E., Ladd, T. B., Minter, L. M., Osborne, B. A., Miele, L., Golde, T. E., & Ran, Y. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ra119.008041 · Cited by 20
He, R., Lai, X., Sun, C., Kung, T., Hong, J., Jheng, Y., Liao, W., Chen, J., Liao, Y., Tu, P., et al. (2019) · Advanced Science · doi:10.1002/advs.201901165 · Cited by 19
Unraveling Alzheimer’s Disease Using Drosophila
Yeates, C. J., Sarkar, A., Kango‐Singh, M., & Singh, A. (2019) · Springer eBooks · doi:10.1007/978-981-13-2218-1_9 · Cited by 24
Zhao, J. X., Su, M., Lin, Y., Liu, H., He, Z., & Lai, L. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01781 · Cited by 20
Bartesaghi, R., Vicari, S., & Mobley, W. C. (2022) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-041521-103641 · Cited by 21
Ramsden, C. E., Keyes, G. S., Calzada, E., Horowitz, M. S., Zamora, D., Jahanipour, J., Sedlock, A., Indig, F. E., Moaddel, R., Kapogiannis, D., et al. (2022) · Journal of Alzheimer's Disease · doi:10.3233/jad-220071 · Cited by 19
The Role of Neurotrophin Signaling in Gliomagenesis
Alshehri, M. M., Robbins, S. M., & Senger, D. L. (2017) · Vitamins and hormones · doi:10.1016/bs.vh.2016.11.001 · Cited by 22
Substrate recruitment by γ-secretase
Fukumori, A., Feilen, L. P., & Steiner, H. (2020) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2020.03.006 · Cited by 22
Inhibiting USP16 rescues stem cell aging and memory in an Alzheimer’s model
Reinitz, F., Chen, E. Y., Nicolis di Robilant, B., Chuluun, B., Antony, J., Jones, R. C., Gubbi, N., Lee, K., Ho, W. H. D., Kolluru, S. S., et al. (2022) · eLife · doi:10.7554/elife.66037 · Cited by 18
Han, F., Xu, H., Shen, J.-X., Pan, C., Yu, Z.-H., Chen, J.-J., Zhu, X.-L., Cai, Y.-F., & Lu, Y.-P. (2020) · Acta Neurobiologiae Experimentalis · doi:10.21307/ane-2020-021 · Cited by 18
“…for the treatment of AD drugs in recent years, including the β secretase in‑ hibitor verubecestat (Egan et al., 2018) and the anti‑Aβ drugs semagacestat (Doody et al., 2013), bapineuzumab (Vandenberghe et al., 2016) and solanezumab (Neurol‑ ogy, 2017), it is even more important to explore new…”
BackgroundVrancx, C., & Annaert, W. G. (2025) · Trends in Neurosciences · doi:10.1016/j.tins.2025.05.007 · Cited by 20
Zhang, Y. C., Li, Z., Guan, H., Qiu, Z., & Zou, C. (2025) · Clinical and Translational Medicine · doi:10.1002/ctm2.70548 · Cited by 21
Aggregation Mechanism of Alzheimer’s Amyloid β-Peptide Mediated by α-Strand/α-Sheet Structure
Balupuri, A., Choi, K.-E., & Kang, N. S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21031094 · Cited by 23
“gov identifier: NCT00594568) [10], have not displayed statistically significant benefits.”
BackgroundTargets, trials and tribulations in Alzheimer therapeutics
Gharat, R., Dixit, G., Khambete, M., & Prabhu, A. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.176230 · Cited by 19
Monoclonal antibody therapy for Alzheimer's disease focusing on intracerebral targets
Gu, X., Long, Q., Qi, Q., Zhou, J., Chen, S., & Wang, L. (2024) · BioScience Trends · doi:10.5582/bst.2023.01288 · Cited by 19
Xie, Y., Ke, X., Ye, Z., Li, X., Chen, Z., Liu, J., Wu, Z., Liu, Q., & Du, X. (2024) · Food & Function · doi:10.1039/d4fo00520a · Cited by 18
Antony, D., Sheth, P., Swenson, A., Smoller, C., Maguire, K., & Grossberg, G. T. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2438317 · Cited by 19
“Lab findings from the phase 3 trial showed that the treatment group also had abnormal levels of immune cells such as reduced lymphocytes, T cells, and immunoglo-bins [56].”
Kang, J., Ryoo, N., Shin, D. W., Trojanowski, J. Q., & Shaw, L. M. J. (2014) · Korean Journal of Physiology and Pharmacology · doi:10.4196/kjpp.2014.18.6.447 · Cited by 21
Gertsik, N., Chau, D.-M., & Li, Y. (2015) · ACS Chemical Biology · doi:10.1021/acschembio.5b00321 · Cited by 18
Alzheimer Mythology: A Time to Think Out of the Box
Morley, J. E., & Farr, S. A. (2016) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2016.06.017 · Cited by 18
The GSM BPN-15606 as a Potential Candidate for Preventative Therapy in Alzheimer’s Disease
Prikhodko, O., Rynearson, K. D., Sekhon, T., Mante, M., Nguyen, P. D., Rissman, R. A., Tanzi, R. E., & Wagner, S. L. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-190442 · Cited by 18
Jin, C., Wang, J., Wang, Y., Jia, B., Guo, X., Yang, G., Xu, P., Greengard, P., Zhou, R., & Shi, Y. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2122292119 · Cited by 18
Multicrossover Randomized Controlled Trial Designs in A lzheimer Disease
Arnold, S. E., & Betensky, R. A. (2018) · Annals of Neurology · doi:10.1002/ana.25280 · Cited by 18
The low-density lipoprotein receptor: Emerging post-transcriptional regulatory mechanisms
Ndoj, K., Meurs, A., Papaioannou, D., Bjune, K., & Zelcer, N. (2025) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2024.119082 · Cited by 17
New Insights into Alzheimer’s Disease: Novel Pathogenesis, Drug Target and Delivery
Chen, H., Xu, J., Xu, H., Luo, T., Li, Y., Jiang, K., Shentu, Y., & Tong, Z. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15041133 · Cited by 17
“Semagacestat (LY450139) γ-secretase Phase 3 (NCT01035138; NCT00762411; NCT00594568) Reduced the production of Aβ in patients; no reduction in cognitive impairment; adverse reactions: increased risk of skin cancer and infection Discontinued [41,81]”
BackgroundKim, J., Jeon, H., Kim, H. Y., & Kim, Y. S. (2023) · ChemBioChem · doi:10.1002/cbic.202300328 · Cited by 17
Hippman, R. S., Snead, A. M., Petros, Z. A., Korkmaz, M. A., Patel, S., Sotelo, D., Dobria, A., Salkovski, M., Nguyen, T. T. A., Linares-Saldana, R., et al. (2023) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.3c00573 · Cited by 17
Unlocking Truths of γ-Secretase In Alzheimer'S Disease: What Is the Translational Potential?
Wolfe, M. S. (2014) · Future Neurology · doi:10.2217/fnl.14.35 · Cited by 18
Proteases at work: cues for understanding neural development and degeneration
Säftig, P., & Bovolenta, P. (2015) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2015.00013 · Cited by 17
“Treated AD patients were also subjected to infections and paradoxically experienced further cognitive decline (Doody et al., 2013).”
Beierlein, J. M., McNamee, L. M., Walsh, M. J., & Ledley, F. D. (2015) · Clinical Therapeutics · doi:10.1016/j.clinthera.2015.07.003 · Cited by 18
Biundo, F., Ishiwari, K., Prete, D. D., & D'adamio, L. (2016) · Oncotarget · doi:10.18632/oncotarget.7389 · Cited by 17
Schaduangrat, N., Prachayasittikul, V., Choomwattana, S., Wongchitrat, P., Phopin, K., Suwanjang, W., Malik, A. A., Vincent, B., & Nantasenamat, C. (2019) · Medicinal Research Reviews · doi:10.1002/med.21563 · Cited by 19
“The failure of semagacestat in phase 3 of the clinical trial is mainly due to serious side effects and its ineffectiveness to improve cognitive functions.(188) Thus, this has driven the development of Notch‐ sparing GSI, namely avagacestat.”
BackgroundWu, P.-C., Fann, M., Tran, T. T., Chen, S.-C., Devina, T., Cheng, I. H.-J., Lien, C., Kao, L., Wang, S., Fuh, J., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-55614-9 · Cited by 18
Anti-Inflammatory Agents: An Approach to Prevent Cognitive Decline in Alzheimer’s Disease
Brod, S. A. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-215125 · Cited by 18
Notch signaling in malignant gliomas: supporting tumor growth and the vascular environment
Kipper, F. C., Kieran, M. W., Thomas, A. J., & Panigrahy, D. (2022) · Cancer and Metastasis Reviews · doi:10.1007/s10555-022-10041-7 · Cited by 19
“Notably, in the phase 3 clinical trial, semagacestat was associated with more adverse events, including skin cancers and infections, resulting in termination of its development by Eli Lilly [109].”
Backgroundvan Maanen, E. M. T., van Steeg, T. J., Ahsman, M. J., Michener, M. S., Savage, M. J., Kennedy, M. E., Kleijn, H. J., Stone, J. A., & Danhof, M. (2018) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.117.244699 · Cited by 17
“The development of the GS inhibitors begacestat (GSI953) (Martone et al., 2009) and semagacestat (LY450139) (Doody et al., 2013) was also stopped.”
BackgroundSvedružić, Ž. M., Popović, K., & Jengić, V. Š. (2015) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2015.06.002 · Cited by 17
“Sadly, all of those trials led to disappointments and in some cases surprisingly daunting results (Doody et al., 2013; Tong et al., 2012).”
Recent insights into viral infections as a trigger and accelerator in alzheimer's disease
Vlieger, L. D., Vandenbroucke, R. E., & Hoecke, L. V. (2022) · Drug Discovery Today · doi:10.1016/j.drudis.2022.103340 · Cited by 17
Cell-specific copper dyshomeostasis mechanism in Alzheimer’s disease
Okafor, M., Faller, P., & Vitale, N. (2025) · Translational Neurodegeneration · doi:10.1186/s40035-025-00504-6 · Cited by 18
“Notch, LRP1, ApoER2, RAGE) [95–98].”
Apolipoprotein E-mediated Modulation of ADAM10 in Alzheimer's Disease
Shackleton, B., Crawford, F., & Bachmeier, C. J. (2017) · Current Alzheimer Research · doi:10.2174/1567205014666170203093219 · Cited by 16
“However, the role of γ-secretase in AD has been well documented and was the focus of several high profile clinical trials targeting γ-secretase activity which ultimately failed to reach their clinical endpoints [9, 10].”
BackgroundEmerging amyloid and tau targeting treatments for Alzheimer’s disease
Khan, A., Corbett, A., & Ballard, C. G. (2017) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2017.1326819 · Cited by 17
“had significant worsening of functional ability, and had more adverse events [80].”
BackgroundEvolving Relevance of Neuroproteomics in Alzheimer’s Disease
Lista, S., Zetterberg, H., O’Bryant, S. E., Blennow, K., & Hampel, H. J. (2017) · Methods in molecular biology · doi:10.1007/978-1-4939-6952-4_5 · Cited by 16
“However, the hypothesis has been challenged by failures of some recent phase III clinical trials aimed at blocking Aβ production, by using secretase inhibitors (49), or enhancing its clearance from the brain, by employing anti-Aβ immunotherapy (50, 51).”
Bax inhibitor 1 is a γ-secretase–independent presenilin-binding protein
Wu, S., Song, W., Wong, C. C. L., & Shi, Y. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1810870116 · Cited by 17
Wuli, W., Tsai, S., Chiou, T., & Harn, H. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21041327 · Cited by 16
“Semagacestat has more adverse effects, including cancers and skin infections (clinical trial number NCT00594568) [65].”
BackgroundAmyloid-β PET Classification on Cognitive Aging Stages Using the Centiloid Scale
de Souza, G. S., Andrade, M. A., Borelli, W. V., Schilling, L. P., Matushita, C. S., Portuguez, M. W., da Costa, J. C., & da Silva, A. M. M. (2021) · Molecular Imaging and Biology · doi:10.1007/s11307-021-01660-7 · Cited by 18
Alzheimer's disease clinical trials: past failures and future opportunities
Yaari, R., & Hake, A. M. (2015) · Clinical Investigation · doi:10.4155/cli.14.127 · Cited by 17
Mutations in the γ-secretase genes PSEN1, PSENEN, and NCSTN in a family with acne inversa
Shi, T.-W., Bai, N., Zhang, J.-A., Lu, F., Chen, X., Kong, X., & Yu, J. (2018) · European Journal of Dermatology · doi:10.1684/ejd.2018.3244 · Cited by 16
Metadata
- Authors
- Doody, R. S., Raman, R., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., He, F., Sun, X., Thomas, R. G., Aisen, P. S., Siemers, E., Sethuraman, G., & Mohs, R.
- Affiliations
- Baylor College of Medicine (US)
- University of California San Diego (US)
- Indiana University (US)
- The University of Tokyo (JP)
- Hôpital de La Grave (FR)
- Boston Children's Hospital (US)
- University of Rochester Medicine (US)
- Eli Lilly (United States) (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2013-07-25
- Volume
- 369
- Issue
- 4
- Pages
- 341-350
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2118935254
- Cited by
- 1,224
- References
- 24
- Citations by year
- 2026: 41 · 2025: 69 · 2024: 85 · 2023: 84 · 2022: 93 · 2021: 91 · 2020: 140 · 2019: 118 · 2018: 109 · 2017: 99 · 2016: 106 · 2015: 88 · 2014: 77 · 2013: 22
- FWCI
- 68.00
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute on Aging (U19AG010483)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- semagacestat, Alzheimer's disease, gamma-secretase inhibitors, amyloid plaques, cognitive decline, activities of daily living, adverse events, skin cancer, lymphopenia, immunosuppression, drug safety, trial termination, dose comparison, ADAS-Cog, amyloid precursor protein, beta-secretase, gamma-secretase, treatment discontinuation
- MeSH terms
- Activities of Daily Living, Aged, Alanine, Alzheimer Disease, Azepines, Cognition, Double-Blind Method, Female, Humans, Male, Middle Aged, Skin Neoplasms, Biomarkers, Weight Loss, Amyloid beta-Peptides, Treatment Failure, Amyloid Precursor Protein Secretases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.